Profund Advisors LLC increased its holdings in Illumina, Inc. (NASDAQ:ILMN – Free Report) by 5.9% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 9,447 shares of the life sciences company’s stock after purchasing an additional 526 shares during the quarter. Profund Advisors LLC’s holdings in Illumina were worth $1,771,000 at the end of the most recent reporting period.
Other hedge funds also recently bought and sold shares of the company. Steward Partners Investment Advisory LLC raised its stake in shares of Illumina by 1.5% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 3,689 shares of the life sciences company’s stock worth $746,000 after buying an additional 54 shares during the period. Venturi Wealth Management LLC raised its position in Illumina by 8.7% during the second quarter. Venturi Wealth Management LLC now owns 751 shares of the life sciences company’s stock worth $141,000 after acquiring an additional 60 shares during the period. Geneos Wealth Management Inc. lifted its holdings in Illumina by 28.6% during the first quarter. Geneos Wealth Management Inc. now owns 270 shares of the life sciences company’s stock valued at $94,000 after purchasing an additional 60 shares in the last quarter. ICICI Prudential Asset Management Co Ltd lifted its holdings in Illumina by 6.2% during the second quarter. ICICI Prudential Asset Management Co Ltd now owns 1,074 shares of the life sciences company’s stock valued at $201,000 after purchasing an additional 63 shares in the last quarter. Finally, Lido Advisors LLC grew its position in shares of Illumina by 3.7% in the second quarter. Lido Advisors LLC now owns 1,752 shares of the life sciences company’s stock valued at $329,000 after purchasing an additional 63 shares during the period. Hedge funds and other institutional investors own 92.17% of the company’s stock.
Analyst Ratings Changes
ILMN has been the subject of several research analyst reports. Barclays reduced their price target on shares of Illumina from $150.00 to $100.00 and set an “underweight” rating for the company in a research report on Friday, September 29th. UBS Group decreased their price target on shares of Illumina from $240.00 to $230.00 and set a “neutral” rating on the stock in a research note on Tuesday, August 8th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $200.00 price target on shares of Illumina in a research note on Thursday, October 12th. JPMorgan Chase & Co. decreased their price target on shares of Illumina from $235.00 to $190.00 and set a “neutral” rating on the stock in a research note on Thursday, August 10th. Finally, Evercore ISI reaffirmed an “outperform” rating and issued a $240.00 price target on shares of Illumina in a research note on Friday, September 1st. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $194.56.
Illumina Trading Up 3.5 %
ILMN opened at $97.61 on Tuesday. The company’s 50 day simple moving average is $123.64 and its two-hundred day simple moving average is $165.31. The firm has a market capitalization of $15.50 billion, a price-to-earnings ratio of -13.71, a price-to-earnings-growth ratio of 6.66 and a beta of 1.16. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.69 and a quick ratio of 1.28. Illumina, Inc. has a 1-year low of $89.00 and a 1-year high of $238.55.
Illumina (NASDAQ:ILMN – Get Free Report) last announced its quarterly earnings results on Thursday, November 9th. The life sciences company reported $0.33 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.13 by $0.20. The business had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a negative net margin of 25.20% and a positive return on equity of 2.13%. The business’s revenue was up .4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.34 EPS. Analysts expect that Illumina, Inc. will post 0.68 EPS for the current fiscal year.
Insider Transactions at Illumina
In other news, SVP Aimee L. Hoyt sold 315 shares of the firm’s stock in a transaction that occurred on Tuesday, November 7th. The shares were sold at an average price of $112.84, for a total transaction of $35,544.60. Following the completion of the sale, the senior vice president now owns 8,314 shares in the company, valued at approximately $938,151.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.13% of the company’s stock.
Illumina, Inc develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; and whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
- Five stocks we like better than Illumina
- What is the S&P/TSX Index?
- Safeguard your portfolio with these three bargain stocks
- How to Invest in Artificial Intelligence
- Membership clubs gain leverage for the consumer rebound
- Comparing and Trading High PE Ratio Stocks
- Advanced Auto Parts may be worth more in pieces than the whole
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.